POTENTIAL OF NON-STEROIDAL ANTI-INFLAMMATORY DRUG DERIVATIVES FOR BLOOD GLUCOSE REGULATION IN TYPE 2 DIABETES MELLITUS
Keywords:
diabetes, NSAIDs, α-glucosidase enzyme inhibition, inflammationAbstract
Type 2 Diabetes Mellitus is a prevalent metabolic disorder characterized by a bidirectional relationship between hyperglycemia and chronic inflammation. This narrative review was conducted through the analysis and synthesis of relevant scientific literature to elucidate the role of inflammation in the pathogenesis of diabetes and the therapeutic effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Evidence from preclinical and clinical studies indicates that NSAIDs reduce pro-inflammatory cytokines, improve insulin resistance, and protect pancreatic beta cells. Structural modification of NSAIDs to enhance their α-glucosidase inhibitory activity has emerged as a promising strategy for glycemic control. These findings suggest that NSAIDs and their derivatives may represent a potential dual-action therapeutic approach for Type 2 Diabetes Mellitus. However, adverse effects on the cardiovascular, renal, and gastrointestinal systems remain major limitations to long-term use. Therefore, further clinical studies and rational structure optimization are required to comprehensively evaluate their efficacy and safety.
References
1. Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a review on recent drug based therapeutics. Biomed Pharmacother. 2020; 131:110708. DOI:10.1016/j.biopha.2020.110708.
2. International Diabetes Federation. Diabetes facts and figures. Accessed 29 June, 2025. https://idf.org/about-diabetes/diabetes-facts-figures/.
3. Bộ Y tế. Việt Nam hiện tỷ lệ người mắc bệnh đái tháo đường đang gia tăng nhanh. Accessed 29 June, 2025. https://moh.gov.vn/tin-noi-bat/-/asset_publisher/3Yst7YhbkA5j/content/viet-nam-hien-ty-le-nguoi-mac-benh-ai-thao-uong-ang-gia-tang-nhanh.
4. Trung tâm DI và ADR Quốc gia. FDA Hoa Kỳ: Đang đánh giá nguy cơ rối loạn tâm thần khi sử dụng các thuốc chủ vận thụ thể GLP-1. Accessed 1 September, 2025. http://canhgiacduoc.org.vn/CanhGiacDuoc/DiemTin/2514/FDA-dang-danh-gia-nguy-co-roi-loan-tam-than-thuoc-chu-van-GLP-1.htm.
5. Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Accessed 1 September, 2025. https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious.
6. Ngọc NTD, Khánh TQ, Kiên TG. Chi phí điều trị của bệnh nhân đái tháo đường nhập viện vì cơn tăng đường huyết tại Khoa Nội tiết Bệnh viện Nguyễn Tri Phương. Tạp chí Y Học Thành phố Hồ Chí Minh. 2024;27(2):27-35. DOI:10.32895/hcjm.m.2024.02.04.
7. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219-246. DOI:10.1146/annurev-physiol-021909-135846.
8. Pollack RM, Donath MY, LeRoith D, Leibowitz G. Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care. 2016;39(Supplement_2):S244-S252. DOI:10.2337/dcS15-3015.
9. Akash MSH, Rehman K, Chen SJJocb. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem. 2013;114(3):525-531. DOI:10.1002/jcb.24402.
10. Luo C, Kallajoki M, Gross R, et al. Cellular distribution and contribution of cyclooxygenase COX-2 to diabetogenesis in NOD mouse. Cell Tissue Res. 2002;310(2):169-175. DOI:10.1007/s00441-002-0628-6.
11. Kimple ME, Keller MP, Rabaglia MR, et al. Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone-stimulated insulin secretion. Diabetes. 2013;62(6):1904-1912. DOI:10.2337/db12-0769.
12. Li J, Zhang N, Ye B, et al. Non-steroidal anti-inflammatory drugs increase insulin release from beta cells by inhibiting ATP-sensitive potassium channels. Br J Pharmacol. 2007;151(4):483-493. DOI:10.1038/sj.bjp.0707259.
13. Lin MH, Wu WT, Chen YC, et al. Association between Non-Steroidal Anti-Inflammatory Drugs use and the risk of type 2 diabetes mellitus: A nationwide retrospective cohort study. J Clin Med. 2022;11(11)DOI:10.3390/jcm11113186.
14. Hanselman EC, Harmon CP, Deng D, et al. Ibuprofen inhibits human sweet taste and glucose detection implicating an additional mechanism of metabolic disease risk reduction. Br J Pharmacol. 2025;182(12):2682-2693. DOI:10.1111/bph.70004.
15. Boztaş FY, Tunalı SJJotTCSSAC. In vitro inhibitory effects of some antiviral, antidiabetic, and Non-Steroidal Anti-Inflammatory Drug active compounds on α-glucosidase and myeloperoxidase activities. JOTCSA. 2024;11(2):691-698. DOI:10.18596/jotcsa.1404431.
16. Singh A, Singh K, Sharma A, et al. Recent developments in synthetic α-glucosidase inhibitors: A comprehensive review with structural and molecular insight. J Mol Struct. 2023;1281:135115. DOI: 10.1016/j.molstruc.2023.135115.
17. Terra W, Ferreira C. Biochemistry and molecular biology of digestion. In: Insect molecular biology and biochemistry. 2012:365-418. DOI:10.1016/B978-0-12-384747-8.10011-X.
18. Akmal M, Patel P, Wadhwa R. Alpha glucosidase inhibitors. In: StatPearls [Internet]. StatPearls Publishing; 2024. Accessed 4 September 2025. https://www.ncbi.nlm.nih.gov/books/NBK557848/.
19. McKinley BJ, Santiago M, Pak C, Nguyen N, Zhong Q. Pneumatosis intestinalis induced by alpha-glucosidase inhibitors in patients with diabetes mellitus. J Clin Med. 2022;11(19):5918. DOI:10.3390/jcm11195918.
20. Barber E, Houghton MJ, Williamson G. Flavonoids as human intestinal α-glucosidase inhibitors. Foods. 2021;10(8):1939. DOI:10.3390/foods10081939.
21. Alam A, Zainab, Elhenawy A, et al. Synthesis of flurbiprofen based amide derivatives as potential leads for diabetic management: In vitro α- glucosidase Inhibition, molecular docking and DFT simulation approach. ChemistrySelect. 2024;9:1-12. DOI:10.1002/slct.202401296.
22. Daud S, Abid OU, Sardar A, et al. Exploring ibuprofen derivatives as α-glucosidase and lipoxygenase inhibitors: Cytotoxicity and in silico studies. Arch Pharm. 2022;355(8):e2200013. DOI:10.1002/ardp.202200013.
23. Daud S, Abid OuR, Saadullah M, et al. Isatin-based ibuprofen and mefenamic acid Schiff base derivatives as dual inhibitors against urease and α–glucosidase: In vitro, in silico and cytotoxicity studies. J Saudi Chem Soc. 2024;28(5):101905. DOI:10.1016/j.jscs.2024.101905.
24. Sardar A, Abid OU, Rehman W, et al. Synthesis and biological evaluation of diclofenac acid derivatives as potential lipoxygenase and α-glucosidase inhibitors. R Soc Open Sci. 2024;11(11):240543. DOI:10.1098/rsos.240543.
25. Sardar A, Abid O-u-R, Daud S, et al. Design, synthesis, in vitro and in silico studies of naproxen derivatives as dual lipoxygenase and α-glucosidase inhibitors. J Saudi Chem Soc. 2022;26(8). DOI:10.1016/j.jscs.2022.101468.
26. Bellucci PN, González Bagnes MF, Di Girolamo G, González CD. Potential effects of Nonsteroidal Anti-Inflammatory Drugs in the prevention and treatment of type 2 diabetes mellitus. J Pharm Pract. 2017;30(5):549-556. DOI:10.1177/0897190016649551.
27. Ahmed N, Jawad A, Mansour A. The potential therapeutic benefit of diclofenac sodium in treatment of patients with type-2 diabetes mellitus. Br J Med Med Res. 2015;9:1-9. DOI:10.9734/BJMMR/2015/19458.
28. Ullah N, Huang Z, Sanaee F, et al. NSAIDs do not require the presence of a carboxylic acid to exert their anti-inflammatory effect - why do we keep using it? J Enzyme Inhib Med Chem. 2016;31(6):1018-1028. DOI:10.3109/14756366.2015.1088840.
29. Abdellatif KR, Abdelall EK, Bakr RB. Nitric Oxide-NASIDS donor prodrugs as hybrid safe anti-inflammatory agents. Curr Top Med Chem. 2017;17(8):941-955. doi:10.2174/1568026616666160927153435.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Thanh Trang Nguyễn, Thị Trâm Nguyễn (Tác giả)
This work is licensed under a Creative Commons Attribution 4.0 International License.
